Rigel Pharmaceuticals | RIGL - Ativos





Ativos Alterar Data
Agenus USD 186.46M 40.34M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Celldex Therapeutics USD 511.25M 71.73M 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Veracyte USD 1.44B 30.38M 2026-03